BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to p...

January 11, 2023 | News

Bio4t2 announces first patient infused with CAR-T targeting solid tumors

"This first-in-human study marks the initial therapeutic to be evaluated from Bio4t2's technology," said Dr. Laurence Cooper MD-PhD, Executive Ch...

January 11, 2023 | News

Cartherics granted first patent in China for multiple development candidates

The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chi...

January 09, 2023 | News

Aurisco cooperates with Cytiva to build its first Oligo FlexFactory for commercial production

Located in Yangzhou of East China, Aurisco's new commercial manufacturing site is expected to produce 200 kilograms of oligonucleotides each year. ...

January 06, 2023 | News

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional...

January 05, 2023 | News

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 (NCT03758417) conducted in China, which evaluated the efficacy and...

January 03, 2023 | News

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery a...

January 03, 2023 | News

China monitors coronavirus mutations to adjust COVID-19 response

"It is a worry," said CNN, citing William Schaffner, professor at the Division of Infectious Diseases of Vanderbilt University Medical Cente...

January 02, 2023 | News

Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19

GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administra...

January 02, 2023 | News

China to downgrade COVID-19 management to Class B

In a statement released late Monday, the National Health Commission (NHC) renamed the Chinese term for COVID-19 from "novel coronavirus pneumonia" to "nove...

December 28, 2022 | News

Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies

"This agreement with Yonghe represents a significant step for Ablaze in our efforts to optimize our preclinical and clinical development program for target...